JTCS St. Jude Medical
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Vivek Rao
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rao, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rao, V.
Related Collections
Right arrow Congestive Heart Failure
Right arrow Transplantation - heart
Right arrowRelated Article

J Thorac Cardiovasc Surg 2005;130:1492-1493
© 2005 The American Association for Thoracic Surgery

Editorial

Stem cell transplantation for ischemic cardiomyopathy: Hope or hype?

Vivek Rao, MD, PhD *

Heart Transplant Program, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada

Received for publication August 12, 2005; accepted for publication August 16, 2005.

* Address for reprints: Vivek Rao, MD, PhD, 4N-464, 200 Elizabeth St, Toronto General Hospital, Toronto, Ontario M5G 2C4, Canada (Email: vivek.rao@uhn.on.ca).

The first 20% of the full text of this article appears below.

UntilGo recently, the adult mammalian heart was considered a terminally differentiated organ incapable of regeneration. Remarkable observational data reported by Anversa and others challenged this dogma and postulated that under appropriate circumstances, the myocardium does indeed have a limited regenerative capacity secondary to a population of pluripotent stem cells. 1,2 Go The last several years have seen a flurry of research activity into the promise of stem cell therapy for end-stage heart disease. The first clinical reports of feasibility further encouraged investigation into this exciting new field. 3 Go As with most new areas of investigation, once the excitement surrounding the initial discovery wanes, the real science begins. 4 Go

In this issue of the Journal, Patel and colleagues 5 Go report preliminary data from a prospective randomized trial in patients subjected to hybrid surgical revascularization with or without autologous bone marrow–derived stem cell injections. The authors are to be congratulated for providing the readership with one of the first prospective surgical evaluations of this new . . . [Full Text of this Article]


Related Article

Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: A prospective randomized study
Amit N. Patel, Luis Geffner, Roberto F. Vina, Jorge Saslavsky, Harold C. Urschel, Jr, Robert Kormos, and Federico Benetti
J. Thorac. Cardiovasc. Surg. 2005 130: 1631-1638. [Abstract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2005 by The American Association for Thoracic Surgery.